drugset

drugset / Trial / NCT05927428

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

NCT05927428 ↗

Phase 2 Recruiting 12 enrolled BRIM Biotechnology Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.

Timeline

Start: 2024-07-31
Primary completion: 2025-08-30
Completion: 2025-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	BRM421	Unknown	—	Topical

Indications